IPM Take
Precision oncology often assumes the tumour can be sampled. Brain tumours expose the flaw in that assumption. If biopsy is unsafe, refused or anatomically impossible, patients can be pushed into less precise care. CSF-based molecular profiling does not remove the need for tissue when tissue is feasible. But it gives neuro-oncology a more realistic pathway when surgery is not.
Executive Summary
Belay Diagnostics announced that the NCCN Clinical Practice Guidelines in Oncology for central nervous system cancers have been updated to expand recommendations for cerebrospinal fluid-based molecular tumour profiling to include inoperable high-grade gliomas and glioblastomas. CancerNetwork reported that updated NCCN guidance now recommends CSF-based tumour-derived DNA testing when direct tissue sampling is not feasible, especially when molecular profiling is needed for diagnosis or therapy selection. The recommendation applies irrespective of the reason biopsy is infeasible, including patient health, patient refusal or tumour location. This is a guideline-access signal, not a claim that CSF testing universally replaces tissue biopsy.
Why it matters
- Patients: Inoperability should not automatically mean exclusion from molecular characterisation.
- Neuro-oncologists: CSF profiling may support diagnosis and therapy selection when tissue cannot be obtained.
- Pathology / laboratories: CNS molecular testing requires validated workflows suited to CSF, not only plasma or tissue.
- Cancer centres: Trial eligibility and treatment matching increasingly depend on molecular information.
Brain cancer has always exposed the limits of easy precision-medicine slogans.
“Test the tumour” sounds simple until the tumour sits in a place where biopsy is dangerous, impossible, or refused by a patient who cannot accept the risk. For patients with high-grade glioma or glioblastoma, the gap between what precision oncology wants and what neurosurgery can safely deliver can become very real.
That is why the NCCN update is important. By expanding consideration of CSF-based molecular profiling in biopsy-infeasible high-grade gliomas and glioblastomas, the guidelines acknowledge a practical truth: molecular diagnosis needs alternative routes when tissue is out of reach.
CSF is not plasma. In central nervous system cancers, cerebrospinal fluid may carry tumour-derived DNA closer to the disease site. That creates a potential route to molecular characterisation through lumbar puncture rather than surgical sampling. The value is especially clear when diagnosis or treatment selection depends on molecular markers.
The language should stay careful. This is not a blanket replacement for tissue biopsy. When safe and feasible, tissue remains central. CSF-based profiling is an adjunctive and alternative route for cases where direct tissue sampling cannot happen.
The access implication is powerful. A patient should not be excluded from precision neuro-oncology simply because the tumour cannot safely be cut. Molecular information can shape diagnosis, therapy selection, prognosis and clinical trial access. Without it, patients may be managed by imaging and limited cytology alone.
For IPM, this is a last-mile diagnostics story. Precision medicine must work for patients whose anatomy, health status or tumour location makes standard pathways impossible. Otherwise, the people with the hardest cancers are left with the least precise care.
